| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Oliver J Ziff | Q85578870 |
| Richard P Steeds | Q86925699 | ||
| Deirdre A Lane | Q87919930 | ||
| Paulus Kirchhof | Q38326091 | ||
| Jonathan N Townend | Q43194026 | ||
| Dipak Kotecha | Q47805074 | ||
| Oliver Ziff | Q56459980 | ||
| Gregory Lip | Q60393087 | ||
| P2093 | author name string | Monica Samra | |
| Michael Griffith | |||
| P2860 | cites work | Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group | Q69913635 |
| Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial | Q70862348 | ||
| Prognostic importance of digitalis after acute myocardial infarction | Q71261377 | ||
| Digoxin therapy and survival in heart failure in sinus rhythm | Q71611640 | ||
| Epidemiology and risk profile of heart failure | Q24630778 | ||
| Digoxin-associated mortality: a systematic review and meta-analysis of the literature | Q27026975 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 | ||
| Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT) | Q28236958 | ||
| Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group | Q28334593 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society | Q29614693 | ||
| Maternal pesticide exposure from multiple sources and selected congenital anomalies | Q29615590 | ||
| What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes | Q29615705 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design | Q30534526 | ||
| Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group | Q30596519 | ||
| Digoxin in patients with permanent atrial fibrillation: data from the RACE II study | Q30830811 | ||
| Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis | Q30847905 | ||
| Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data | Q31111736 | ||
| Digoxin associates with mortality in ESRD. | Q34455390 | ||
| Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial | Q34474439 | ||
| Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction? | Q72020121 | ||
| Association of serum digoxin concentration and outcomes in patients with heart failure | Q73004928 | ||
| Digoxin and mortality in chronic heart failure. UK Heart Investigation | Q73029219 | ||
| The effect of digoxin on mortality and morbidity in patients with heart failure | Q73080377 | ||
| Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure | Q73128844 | ||
| Calcium Channel Blockers in Heart Failure | Q74505991 | ||
| Are coronary patients at higher risk with digoxin therapy? An ongoing controversy | Q77213439 | ||
| Causal diagrams for epidemiologic research | Q77794178 | ||
| Declining public health burden of digoxin toxicity from 1991 to 2004 | Q80228560 | ||
| Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis | Q80959280 | ||
| Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study | Q82553268 | ||
| Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure | Q83142850 | ||
| Digoxin use and digoxin toxicity in the post-DIG trial era | Q83953776 | ||
| Increased mortality among patients taking digoxin--analysis from the AFFIRM study | Q85551923 | ||
| Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis | Q87164419 | ||
| Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta-Blocker Heart Attack Trial | Q93617320 | ||
| Digitalis-associated cardiac mortality after myocardial infarction | Q93861589 | ||
| Lifetime risk for development of atrial fibrillation: the Framingham Heart Study | Q34550202 | ||
| Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort study | Q34573036 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Digoxin and mortality in atrial fibrillation: a prospective cohort study | Q34660772 | ||
| Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Tr | Q34668487 | ||
| Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy | Q35096835 | ||
| Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study | Q35102218 | ||
| A definition of causal effect for epidemiological research | Q35415092 | ||
| Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study | Q35511302 | ||
| Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK | Q35582163 | ||
| Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis | Q35752516 | ||
| Controlling the risk of spurious findings from meta-regression. | Q35782230 | ||
| Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort | Q35789263 | ||
| Observational cohort study of the safety of digoxin use in women with heart failure | Q35904187 | ||
| Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial | Q36776095 | ||
| Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial | Q36860117 | ||
| Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. | Q36915750 | ||
| Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial | Q37066497 | ||
| Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure | Q37077866 | ||
| Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations | Q37131733 | ||
| Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction | Q37255465 | ||
| Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study | Q37543186 | ||
| Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure | Q37594550 | ||
| Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure | Q37599290 | ||
| Interaction between digoxin and dronedarone in the PALLAS trial | Q38421149 | ||
| Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry | Q38943915 | ||
| Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation | Q41626846 | ||
| Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study | Q41724146 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val‐HeFT) | Q42871640 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy | Q43266268 | ||
| The mortality risk associated with digitalis treatment after myocardial infarction | Q43607094 | ||
| International subarachnoid aneurysm trial of neurosurgical clipping versus endovascular coiling: subgroup analysis of 278 elderly patients | Q43892890 | ||
| A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure | Q43973759 | ||
| ??? | Q28267062 | ||
| When 'digoxin use' is not the same as 'digoxin use': lessons from the AFFIRM trial | Q43985351 | ||
| International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial | Q44203470 | ||
| Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 | ||
| Digitoxin-associated mortality in acute myocardial infarction | Q44362305 | ||
| Effect of digitalis treatment on survival after acute myocardial infarction | Q44645984 | ||
| The effects of digitalis on survival in high-risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS). | Q44787981 | ||
| Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity | Q44948737 | ||
| Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis | Q45187902 | ||
| The effect of gender on outcome in digitalis-treated heart failure patients | Q45283101 | ||
| Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function | Q45365558 | ||
| Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. | Q46095564 | ||
| Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. | Q46548662 | ||
| Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy | Q46960475 | ||
| A cohort study of digoxin exposure and mortality in men with prostate cancer | Q47797325 | ||
| Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure | Q50597542 | ||
| What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial | Q50732508 | ||
| Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study | Q51031013 | ||
| Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). | Q51617706 | ||
| In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias | Q51967379 | ||
| Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation | Q53569088 | ||
| The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry. | Q54419973 | ||
| Digitalis Use in Contemporary Clinical Practice | Q56534880 | ||
| Digoxin in advanced heart failure patients: A question of rhythm | Q58327554 | ||
| Should digoxin be proscribed in elderly subjects in sinus rhythm free from heart failure? A population-based study | Q62113347 | ||
| Exercise capacity and quality of life in the treatment of heart failure | Q68427970 | ||
| Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study | Q68857763 | ||
| Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group | Q69013550 | ||
| A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure | Q69487946 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| meta-analysis | Q815382 | ||
| atrial fibrillation | Q815819 | ||
| carbohydrate | Q11358 | ||
| digoxin | Q422222 | ||
| polycyclic compound | Q426145 | ||
| systematic review | Q1504425 | ||
| cardiotonic | Q2938102 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | h4451 | |
| P577 | publication date | 2015-08-30 | |
| P13046 | publication type of scholarly work | systematic review | Q1504425 |
| review article | Q7318358 | ||
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data | |
| P478 | volume | 351 |
| Q34677347 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib |
| Q38654100 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial |
| Q30240765 | Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis |
| Q39075410 | Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure |
| Q26784426 | Atrial fibrillation in heart failure: what should we do? |
| Q88711647 | Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure? |
| Q42673198 | Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality |
| Q37443847 | Clinical characteristics and prognostic impact of atrial fibrillation in patients with chronic heart failure. |
| Q38970521 | Contemporary Controversies in Digoxin Use in Systolic Heart Failure |
| Q31119031 | Data quality evaluation for observational multiple sclerosis registries |
| Q51769291 | Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model |
| Q47648452 | Digoxin Is Associated With Increased Shock Events and Electrical Storms in Patients With Implantable Cardioverter Defibrillators. |
| Q38374710 | Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial |
| Q55280835 | Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study. |
| Q64903815 | Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. |
| Q43113878 | Digoxin and mortality: lessons for observational studies |
| Q93022817 | Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction |
| Q37739398 | Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis |
| Q92843260 | Digoxin-mortality: randomized vs. observational comparison in the DIG trial |
| Q99409927 | Improved 30 day heart failure rehospitalization prediction through the addition of device-measured parameters |
| Q55466898 | In-hospital major arrhythmias, arrhythmic death and resuscitation after successful primary percutaneous intervention for acute transmural infarction: a retrospective single-centre cohort study. |
| Q37624266 | Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis |
| Q38848144 | Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. |
| Q41472411 | Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium |
| Q88104837 | Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis |
| Q49427362 | Observational research rigour alone does not justify causal inference |
| Q36179407 | Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties |
| Q39445718 | Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management |
| Q38998634 | Pharmacogenomics of heart failure: a systematic review |
| Q39008761 | Potentially inappropriate medications: predictor for mortality in a cohort of community-dwelling older adults |
| Q59128777 | Primary versus secondary source of data in observational studies and heterogeneity in meta-analyses of drug effects: a survey of major medical journals |
| Q64271889 | Quantitative Detection of Digoxin in Plasma Using Small-Molecule Immunoassay in a Recyclable Gravity-Driven Microfluidic Chip |
| Q38936964 | Rate control in atrial fibrillation |
| Q92501606 | Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study |
| Q39410727 | Rationales and choices for the treatment of patients with NYHA class II heart failure |
| Q92353984 | Saudi Heart Association (SHA) guidelines for the management of heart failure |
| Q89843548 | Should Digoxin Continue To Be Used for the Management of Atrial Fibrillation? |
| Q31155016 | Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance |
| Q91915544 | The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics |
| Q38688877 | The future of atrial fibrillation management: integrated care and stratified therapy |
| Q101211273 | The impact of serum concentration-guided digoxin therapy on mortality of heart failure patients: A long-term follow-up, propensity-matched cohort study |
| Q39303486 | The intensive care medicine research agenda on septic shock |
| Q38910426 | The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice |
| Q47614330 | Venous-to-arterial carbon dioxide difference: an experimental model or a bedside clinical tool? |
Search more.